The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report

BACKGROUND: Systemic treatment of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the introduction of targeted therapies. The analysis of circulating tumor DNA (ctDNA) is a valuable approach to monitor the clonal evolution of tumors during treatment with EGFR-tyrosine kina...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Re, Marzia, Rofi, Eleonora, Cappelli, Carla, Puppo, Gianfranco, Crucitta, Stefania, Valeggi, Simona, Chella, Antonio, Danesi, Romano, Petrini, Iacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492432/
https://www.ncbi.nlm.nih.gov/pubmed/31039766
http://dx.doi.org/10.1186/s12885-019-5604-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492432/
https://www.ncbi.nlm.nih.gov/pubmed/31039766
http://dx.doi.org/10.1186/s12885-019-5604-6

Ejemplares similares